LC Investigación Logo
LC Research Logo
EN ES
Contact

Infrastructure and Scientific Leadership

A facility designed under international standards (ICH-GCP) for the safe, ethical, and efficient conduct of high-complexity oncology clinical trials.

Medical & Scientific Leadership

Principal Investigators

Dr. Mónica Casalnuovo

Dr. Mónica Lis Casalnuovo

Executive Director / Principal Investigator

Specialist in Clinical Oncology and Internal Medicine, with postgraduate training in Molecular Biology, Targeted Therapies, and Hereditary Tumors. She has extensive and ongoing training in GCP (Good Clinical Practice), ensuring the highest regulatory standards and patient safety in the development of international Clinical Trials.

  • Specialization: Clinical Oncology, Molecular Biology, Targeted Therapies, and Genetic Counseling.
  • Publications: Author in JCO Global Oncology (ASCO) and co-author in The New England Journal of Medicine and Annals of Oncology.
  • Memberships: BIG, GAICO, LACOG, ESMO, ASCO and AAOC.
  • Research Experience: Principal Investigator in multiple oncology Clinical Trials since 2009.
Dr. Guillermo Lerzo

Dr. Guillermo Luis Lerzo

Medical Director / Principal Investigator

Graduated from UBA and Head of the Clinical Oncology Unit at María Curie Oncology Hospital for more than 20 years (2003-2023). He is an internationally recognized expert with extensive experience leading multicenter clinical trials, bringing unmatched academic and clinical insight to our center.

  • Specialization: Clinical Oncology (National Ministry of Health).
  • Publications: More than 20 publications in high-impact journals, including The Lancet, Journal of Clinical Oncology (JCO), The New England Journal of Medicine and Breast Cancer Research and Treatment.
  • Memberships: ASCO, EUSOMA, BIG, LACOG, GAICO and ESMO.
  • Research Experience: Investigator in globally relevant Phase II and III clinical trials since 2001.

Medical & Operational Team

We have a multidisciplinary team of Sub-Investigators and Study Coordinators trained under ICH-GCP regulations to ensure rigor in data collection and patient care.

Dr. Baltz Hehn

Principal Investigator / Medical Manager

Physician (UAI) and Specialist in Clinical Oncology (USAL), with residency at María Curie Oncology Hospital. Her profile stands out for strong academic training, while currently pursuing a Master's degree in Pharmacology and Clinical Research. She leads high-complexity international Clinical Trials in oncology (DS1062, R3767, D5086C). She completed rotations at Instituto Fleming and Roffo, and holds updated GCP certification (2025).

Dr. Javier Leveroni

Clinical Sub-Investigator

Physician graduated from UBA and Clinical Oncologist with residency at María Curie Oncology Hospital. Staff physician at Hospital J. M. Penna (Buenos Aires) and Hospital Cuenca Alta Néstor Kirchner.

Dr. Tomas Valdemarin

Clinical Sub-Investigator

Clinical Oncologist at María Curie Oncology Hospital. Specialized in research and actively training in the comprehensive management of Gastrointestinal Tumors.

Dr. Sebastián Leglise

Clinical Sub-Investigator

Clinical Oncologist trained at UBA and María Curie Oncology Hospital. His research interests focus on the development of Clinical Trials for genitourinary and lung tumors.

Dr. Adriana López

Clinical Sub-Investigator

Physician with residency in Internal Medicine (Hospital Santojanni), specialized in Palliative Care. Staff physician at Clínica San Camilo and in LUCEN palliative care outpatient clinics.

Dr. Abril Acosta

Clinical Sub-Investigator
Physician graduated with honors from the University of Buenos Aires (2011–2017). Specialist in Clinical Oncology (UBA), with residency and chief residency at María Curie Oncology Hospital (2018–2023). She holds a diploma in Clinical Research from the Catholic University of Argentina (2025).

Dr. Ana Amanda Camporini

Clinical Sub-Investigator
Physician specialized in Internal Medicine (UBA), with training in Nutrition (UCA) and Medical Law (USAM). She holds postgraduate research training from CONICET. She currently works as an inpatient staff physician at Hospital Donación Francisco Santojanni and in outpatient clinics at Swiss Medical Group.

Dr. María José Favere

Clinical Sub-Investigator
Fourth-year resident physician in Clinical Oncology at Hospital Ramos Mejía, with experience in the comprehensive management of oncology patients in high-complexity settings. With a strong commitment to teaching and academic development, she participates in coordinating learning spaces for colleagues in training.

Protocolos

A Track Record That Supports Our Science

Decades of clinical experience and commitment to oncology research, reflected in tangible results and strategic partnerships with the global industry.

🤝
+ 0

International Sponsors

Laboratories and CROs that trust our center.

🔬
+ 0

Studies Conducted

Phase II, III, and IV clinical studies successfully carried out.

👥
+ 0

Patients Treated

People who gained access to innovative therapies.

Quality Assurance & Compliance

Scientific rigor with competitive start-up timelines

We operate under strict Standard Operating Procedures (SOPs) and a strong ethical commitment. We streamline local regulatory processes to ensure an agile start-up and effective recruitment for every clinical study.

Check Feasibility View Research Areas

High-Impact Evidence

Our research team actively contributes to publications and co-authorships in the world’s most prestigious scientific journals.

The New England Journal of Medicine

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer (EMBER-3)

Co-author: Dr. Mónica Casalnuovo
The New England Journal of Medicine

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

Co-author: Dr. Mónica Casalnuovo
Annals of Oncology

Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer

Co-author: Dr. Mónica Casalnuovo
San Antonio Breast Cancer Symposium (SABCS)

Abstract RF705 – SABCS 2025

Co-author: Dr. Guillermo Lerzo
European Journal of Cancer

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer

Co-author: Dr. Guillermo Lerzo
The Lancet

Everolimus for women with trastuzumab-resistant HER2-positive advanced breast cancer (BOLERO-3)

Co-author: Dr. Guillermo Lerzo
View full study record.

Medical center dedicated to conducting highly complex oncology clinical trials, combining local expertise with the highest ethical and international standards.

Sections

Quick Access
QR code to access the LC Research website

Scan to visit the website

Contact

© 2026 LC Clinical Oncology Research. All rights reserved.
We operate under ANMAT regulations and ICH-GCP guidelines. Privacy Policy Terms of Use